All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
Phase 1/1b Study To Evaluate The Safety And Activity Of TTX-030 (Anti-CD39) In Combination With Budigalimab And/Or Chemotherapy In Subjects With Advanced Solid Tumors
To test the safety of TTX-030 combination therapy in various cancer types
To see if TTX-030 combination therapy works against various cancer types
To see how much TTX-030 combination therapy is in the blood at specific times after dosing and how the body eliminates TTX-030
To see what effects TTX-030 combination therapy has on the body
A Phase I/II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naïve Metastatic Clear Cell Renal Cell Carcinoma Patients
PD-Inhibitor (Nivolumab) and Ipilimumab followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
advanced kidney cancer, by adding a drug called cabozantinib to another treatment after
receiving the standard treatment?